SCHEMBL4136528

SCHEMBL4136528

COc1cc(Nc2ccc3c(c2)NC(=O)C3=Cc2ccc[nH]2)cc(C(N)=O)c1

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 8/20 0.68
FLT3 P36888 10/20 0.66
FLT4 P35916 6/20 0.66
KDR P35968 6/20 0.66
KIT P10721 5/20 0.66
PDGFRB P09619 3/20 0.64
NTRK3 Q16288 2/20 0.61
TLK2 Q86UE8 1/20 0.61
NTRK1 P04629 2/20 0.59
PDPK1 O15530 1/20 0.55
AURKA O14965 1/20 0.54
PDGFRA P16234 1/20 0.54
AURKC Q9UQB9 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136534 0.87 TLK2 (0.66) AURKBFLT3FLT4KDRKIT
SCHEMBL3599506 0.84 FLT3 (0.77) AURKBFLT3FLT4KDRKIT
SCHEMBL3599504 0.84 FLT3 (0.77) AURKBFLT3FLT4KDRKIT
SCHEMBL3603444 0.82 FLT3 (0.80) AURKBFLT3FLT4KDRKIT
SCHEMBL3603441 0.82 FLT3 (0.80) AURKBFLT3FLT4KDRKIT
SCHEMBL15328123 0.81 AURKB (1.00) AURKBFLT3FLT4KDRKIT
SCHEMBL15328125 0.81 AURKB (1.00) AURKBFLT3FLT4KDRKIT
SCHEMBL27781584 0.79 FLT3 (0.57) AURKBFLT3FLT4KDRKIT
SCHEMBL15328030 0.78 FLT3 (1.00) AURKBFLT3FLT4KDRKIT
SCHEMBL18060032 0.78 FLT3 (1.00) AURKBFLT3FLT4KDRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101056632-B Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2011-12-07 CN claimed
EP-1814545-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-06-10 EP claimed
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-11 US claimed
EP-1814545-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-08-08 EP claimed
WO-2006052936-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-18 WO claimed
CN-101056632-B Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2011-12-07 CN disclosed
EP-1814545-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-06-10 EP disclosed
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-11 US disclosed
EP-1814545-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-08-08 EP disclosed
WO-2006052936-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-18 WO disclosed
CN-1151187-A Subtilisin 309 variants having decreased absorption and increased hydrolysis PROCTER & GAMBLE (US) 1997-06-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors BMX, FRK, PTK2B AURKB 164/4885FLT3 93/4885FLT4 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.